WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh

World Vape Show by 2FIRSTS
Jun.14.2024
WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
World Vape Show in Dubai featured ANYX brand leader Sanking discussing market performance, new products, and future plans.

The World Vape Show was held at the Dubai World Trade Center from June 12th to 14th. During the event, 2FIRSTS had a conversation with Sanking, the head of Anyx, a brand under the Yijiate Group, where he discussed the market performance of Anyx, new products, and future development plans.

WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
ANYX booth | Image source: 2FIRSTS

 

According to Sanking, the ANYX brand specializes in pod systems, including both open and closed systems, and also has entered the disposable e-cigarette market. The brand is continuously innovating its technology and has recently launched four new products, including Anyx-pro, Anyx-go, Anyx-polo, and Anyx-max.

WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
ANYX booth | Image source: 2FIRSTS

 

Sanking stated that ANYX primarily focuses its market in Europe, particularly in Italy and Spain, as well as in South America, the Middle East, and Southeast Asia, with the best performance seen in the Italian market. The brand name "ANYX" combines "any + possible," symbolizing endless possibilities and emphasizing user needs and perception.

 

This is ANYX's first participation in the world e-cigarette exhibition in Dubai. The Middle East market is a completely new territory for ANYX, as the brand only started expanding into this market at the end of 2022. Sanking stated that despite being a relatively new brand, the Middle East market will be a strategic focus for future extensive deployment.

 

At this exhibition, ANYX showcased its latest atomization core technology G-mesh and the products using it. While ANYX introduced a large-screen e-cigarette based on cartridge replacement, it remains cautious towards disposable large-screen e-cigarettes due to concerns about resource waste and environmental issues.

 

Sanking stated that the Middle East market has tremendous potential, and ANYX is currently in discussions with multiple local distributors for collaboration. The brand's plan is to combine online and offline experiences and user operations to increase market share. In the future, ANYX will launch products that better cater to the preferences of local consumers based on market demand, and will collaborate deeply with local partners.

 

Sanking stated that ANYX will focus on the European market and continue to explore opportunities in other emerging markets in the future. The brand will introduce products tailored to consumer demands based on market conditions, aiming to enhance user experience through technological innovation.

 

Finally, Sanking gave high praise to the e-cigarette exhibition in Dubai, considering it the largest in the world with significant influence. The large number of exhibitors, distributors, and visitors, along with intense competition, reflects the industry's enormous potential and development trends.

 

He called on all industry participants to focus on the product itself and user experience, rather than solely concentrate on price wars.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08